Program
Monday 9 September
09:00
09:15
09:45
09:50
Session 1: The Tumor Microenvironment, Metastasis and Therapy Resistance
Chair: Therese Sørlie
10:15
10:35
10:40
10:50
10:55
11:15
11:20
11:30
11:35
11:55
12:00
13:00
14:00
15:00
Session 2: Risk Stratification, Current and Emerging Treatment regimens
Chair: Gunhild M. Mælandsmo
15:20
15:40
15:45
15:55
16:00
16:20
16:25
16:35
16:40
17:00
17:05
19:00
19:30
Tuesday 10 September
Session 3: Norwegian Cancer Research
Chair: Eirik Malinen
09:00
09:20
09:25
09:45
09:50
Session 4: Computational and Functional Precision Cancer Medicine
Chair: Leonardo Meza-Zepeda
10:20
10:40
10:45
10:55
11:00
11:20
11:30
Session 4: Computational and Functional Precision Medicine - continued
12:30
12:40
12:45
13:05
Session 5: Cancer Immunology and Immunotherapy
Chair: Harald Stenmark
13:10
13:30
13:35
13:45
13:50
14:20
14:40
14:45
14:55
15:00
15:20
15:25
– 09:15
– 09:45
– 09:50
– 10:15
– 10:35
– 10:40
– 10:50
– 10:55
– 11:15
– 11:20
– 11:30
– 11:35
– 11:55
– 12:00
– 13:00
– 14:00
– 15:00
– 15:20
– 15:40
– 15:45
– 15:55
– 16:00
– 16:20
– 16:25
– 16:35
– 16:40
– 17:00
– 17:05
– 19:00
- 09:20
- 09:25
- 09:45
- 09:50
- 10:20
- 10:40
- 10:45
- 10:55
- 11:00
- 11:20
- 11:25
- 12:30
- 12:40
- 12:45
- 13:05
- 13:10
- 13:30
- 13:35
- 13:45
- 13:50
- 14:20
- 14:40
- 14:45
- 14:55
- 15:00
- 15:20
- 15:25
- 15:30
Opening addresses (Chair: Kjetil Taskén)
Keynote: Douglas Hanahan, Ludwig Institute for Cancer Research and Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland
The Hallmarks of Cancer in 2024
Q&A
Coffee break
Johanna Ivaska, University of Turku, Finland
Pathways limiting cancer progression
Q&A
Short talk selected from abstracts: José Teles Reis, Institute for Cancer Research, Oslo University Hospital
Dissecting the mutational drivers behind interclonal interactions in Cancer
Q&A
Erik Sahai, The Francis Crick Institute, London, UK
Mechanisms of resistance to targeted therapy
Q&A
Short talk selected from abstracts: Astrid Medhus, Institute for Cancer Research, Oslo University Hospital
Biomarker guided ADC therapy
Q&A
Verena Jendrossek, University Hospital Essen, Germany
Tumor microenvironment, cancer metabolism and radioresistance
Q&A
Poster session 1, part 1 (Odd-numbered posters)
Lunch
Poster session 1, part 2 (Odd-numbered posters)
Coffee break
Olli Kallioniemi, Karolinska Institutet & SciLifeLab, Stockholm, Sweden
Data-driven Cancer Hallmarks
Q&A
Short talk selected from abstracts: Mev Domingues-Valentin, Institute for Cancer Research, Oslo University Hospital
Towards precision medicine in Lynch Syndrome
Q&A
Sibylle Loibl, Goethe-Universität Frankfurt, Germany
Recent advancement in the treatment of HER2-negative early breast cancer and what biomarkers have taught us
Q&A
Short talk selected from abstracts: Mary-Ann Jallad, Institute for Cancer Research, Oslo University Hospital
High-throughput Combination Drug Screening to Overcome Resistance in Breast Cancer
Q&A
Manuel R Teixeira, IPO Porto, Portugal
Uncovering the missing heritability of prostate cancer
Q&A
Poster session 2 (Even-numbered posters)
Aperitif Reception Area
Banquet Dinner
Per Eystein Lønning, Haukeland University Hospital and University of Bergen, Norway
Prenatal epimutations and cancer risk; a phenomenon affecting a few, or a major risk factor in certain cancer forms?
Q&A
Ragnhild A. Lothe, Institute for Cancer Research, Oslo University Hospital
70-year History of the Institute for Cancer Research
Q&A
Coffee break
Berend Snijder, ETH Zürich, Switzerland
Probing single-cell biology ex vivo for personalized systems medicine
Q&A
Short talk selected from abstracts: Chloe Steen, Institute for Cancer Research, Oslo University Hospital
Pan-cancer Cartography of Human Tumors with CytoSPACE
Q&A
Karuna Ganesh, Memorial Sloan Kettering Cancer Centre
Dissecting plasticity during colorectal cancer metastasis
Q&A
Lunch
Short talk selected from abstracts: Kushtrim Kryeziu, Institute for Cancer Research, Oslo University Hospital
Patient-derived organoids from metastatic colorectal cancer for functional precision oncology
Q&A
Anita Sveen, Institute for Cancer Research, Oslo University Hospital
Tumor heterogeneity of treatment response and progression of colorectal cancer
Q&A
Gillian Griffiths, University of Cambridge, UK
Mechanisms of Cytotoxic T-Lymphocyte killing
Q&A
Short talk selected from abstracts: Inga Hansine Rye, Institute for Cancer Research, Oslo University Hospital
Tumor size is key driver of local immunological changes in breast cancer
Q&A
Coffee break
Reuven Agami, The Netherlands Cancer Institute
Amino acid substitutants, cancer development, and anti-tumor immunity
Q&A
Short talk selected from abstracts: Edina Szabo, Institute for Cancer Research, Oslo University Hospital
TIGIT modulates the mitochondrial-metabolism axis and preserves fitness in circulating effector memory T cells
Q&A
Johanna Olweus, Institute for Cancer Research, Oslo University Hospital
Opportunities for therapeutic T-cell receptors in cancer immunotherapy
Q&A
Closing words